Τόμος 6 (1988) – Τεύχος 1 – Άρθρο 4 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 6 (1988) – Issue 1 – Article 4 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

6: 43-53 (1988)

PHARMAKON-Press: Epitheorese Klin. Farmakol. Farmakokinet.

6: 43-53 (1988)

Dose limiting toxicity of 5-Fluοrouracil is a problem in chemotherapy which includes this agent. Allopurinol protects the normal cell whereas promotes the metabolism of 5-­fluorouracil in cancer cells. In our effort to evaluate the protective effect of allopurinol we gave high doses 5-fluorouracil alone or in combination with other cytostatics. In certain patients 5-fluorouracil was given for 5 days, while allopurinol was given in a dose of 900 mg per day for 21 days, started 4 days before 5-fluorouracil administration. Toxicity was mild to moderate, and usually well accepted by patients. Mucositis and bone marrow toxicity were the two major side effects which were controlled in spite of the high dose of 5-fluorouracil.

1. Corbett, Τ.H., Griswold, D.Ρ. Jr., Roberts, B.J., Peckham, J.C., Schabel, F.M. Jr.: Α mouse colon tumor model for experimental therapy. Cancer Chemother. Rep., Part II, 5: 169 (1985)
2. Curreri, A.R., Ansfield, F.J., McIver, F.A., Waisman, H.A., Heildelberger, C.: Clinical studies with 5-fluorοuracil. Cancer Res., 18: 478 (1985)
3. Gold, G.L., Hall, T.C., Shnider, B.I., Selawry, O., Colsky, J., Owens, A.M. Jr., Dederick, M.M., Holland, J.F., Brindley, C.O., Jones, R.: Α clinical study of 5-fluorouracil. Cancer Res., 19: 935 (1959)
4. Spears, C.P., Shehinian, A.H., Moran, R.G.: In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sen­sitivity and resistance murin colon adenocarcinomas. Cancer Res. 42: 450 (1982)
5. Houghton, J.A., Houghton, P.J.: Combination of 5-FU, Hypoxanthine and Allopurinol in Chemotherapy for human colon adenocarcinoma xenografts. Cancer Treat. Rep., 66: 1201 (1982)